A separate study examined the peripheral TCR repertoire in anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)–treated patients with prostate cancer or melanoma and found that clonotype stability was associated with response [16]. Here, CTLA4 is linked to prostate carcinoma.